K. Horwood
Publications by Year
Research Areas
Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Ovarian cancer diagnosis and treatment, Lung Cancer Research Studies, PARP inhibition in cancer therapy
Most-Cited Works
- → Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors(2017)256 cited
- → Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses(2015)104 cited
- → Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival(2003)38 cited
- → Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer(2014)35 cited
- → The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)(2008)14 cited
- → Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study(2007)13 cited
- → Primary vaginal non‐Hodgkin's lymphoma after radiotherapy for Hodgkin's disease(2000)
- → Novel histological determinants of outcome in surgically resected non-small cell lung cancer (NSCLC)(2000)
- → P-554 Randomized Phase II study of first-line docetaxel (D)/ gemcitabine (G) doublet chemotherapy versus fixed duration (3 cycles) sequential single agent chemotherapy (D then G) in Stage IIIB/IV non-small cell lung cancer (NSCLC)—Final Results. A study by the NSW and Australian Lung Cancer Trials Group(2005)